Novartis cancer drug Zykadia gets FDA priority review

ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday.